×
Molecular Templates Total Assets 2010-2024 | MTEM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Molecular Templates total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
View More
Molecular Templates Total Assets 2010-2024 | MTEM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Molecular Templates total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$77.1B
Chugai Pharmaceutical (CHGCY)
$71.1B
Takeda Pharmaceutical (TAK)
$42.6B
Sandoz Group AG (SDZNY)
$21B
Merck (MKKGY)
$19.6B
Astellas Pharma (ALPMY)
$17.5B
Summit Therapeutics (SMMT)
$15.9B
United Therapeutics (UTHR)
$15.7B
Neurocrine Biosciences (NBIX)
$15.4B
Shionogi (SGIOY)
$13B
Orion OYJ (ORINY)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.3B
Corcept Therapeutics (CORT)
$7B
Stevanato Group S.p.A (STVN)
$6.8B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ionis Pharmaceuticals (IONS)
$5B
Grifols, S.A (GRFS)
$4.7B
Ono Pharmaceutical (OPHLF)
$4.3B
Crinetics Pharmaceuticals (CRNX)
$3.7B
Recursion Pharmaceuticals (RXRX)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Centessa Pharmaceuticals (CNTA)
$2.2B
Soleno Therapeutics (SLNO)
$2.2B
NewAmsterdam Pharma (NAMS)
$2.1B
Hypermarcas (HYPMY)
$2B
Indivior (INDV)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Evotec AG (EVO)
$1.6B
Dyne Therapeutics (DYN)
$1.4B